Core Insights - NAYA Biosciences is expanding its bifunctional antibody pipeline with a novel PD-1 x VEGF tetravalent bifunctional antibody, NY-500, targeting hepatocellular carcinoma (HCC) and other solid tumors, aiming to initiate clinical trials in early 2026 [1][4] Company Overview - NAYA Biosciences is a life science portfolio company focused on breakthrough treatments in oncology, autoimmune diseases, and women's health, utilizing a hub & spoke model for efficient asset development and partnering [5] Product Pipeline - The company is leveraging its proprietary FLEX antibody platform and collaborating with MabSilico to optimize the design of new therapeutic candidates [2] - NY-500 is designed to synergistically target PD-1 and VEGF, enhancing T-cell infiltration and immune response while disrupting tumor vasculature, with recent data showing its potential superiority over existing therapies [4] - NAYA is also developing NY-303, a GPC3-targeting bifunctional antibody, currently in a phase 1/2 clinical trial for HCC patients who do not respond to PD-1 +/- VEGF therapy, with data indicating its ability to reverse resistance to immunotherapy [3][6] Market Potential - The PD(L)1 market is projected to exceed $50 billion in 2025, indicating significant growth opportunities for NAYA's innovative therapies [4]
NAYA Biosciences Announces Development of NY-500, a Novel AI-Optimized PD-1 x VEGF Bifunctional Antibody